{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:28:01Z","timestamp":1648744081791},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11938-004-0041-1","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T15:27:35Z","timestamp":1180884455000},"page":"201-211","source":"Crossref","is-referenced-by-count":0,"title":["Refractory inflammatory bowel disease"],"prefix":"10.1007","volume":"7","author":[{"given":"Karl H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"41_CR1","first-page":"2005","volume-title":"Sleisenger & Fordtran\u2019s Gastrointestinal and Liver Disease.","author":"BE Sands","year":"2002","unstructured":"Sands BE: Crohn\u2019s disease. In Sleisenger & Fordtran\u2019s Gastrointestinal and Liver Disease. Edited by Feldman M, Friedman LS, Sleisenger MH: Philadelphia: WB Saunders; 2002: 2005\u20132038."},{"key":"41_CR2","first-page":"77","volume-title":"Advanced Therapy of Inflammatory Bowel Disease","author":"AI Rogers","year":"2001","unstructured":"Rogers AI: Pseudo-intractability of inflammatory bowel disease. In Advanced Therapy of Inflammatory Bowel Disease, edn 1. Edited by Bayless TM, Hanauer SB. Hamilton, ON: BC Decker; 2001: 77\u201380.","edition":"edn 1"},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJM197308022890506","volume":"289","author":"B Blackwell","year":"1973","unstructured":"Blackwell B: Drug therapy: patient compliance. N Engl J Med 1973, 289: 249\u2013252.","journal-title":"N Engl J Med"},{"key":"41_CR4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ: Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955, 2: 1041\u20131088.","journal-title":"BMJ"},{"key":"41_CR5","first-page":"221","volume-title":"The Clinician\u2019s Guide To Inflammatory Bowel Disease.","author":"R Srinivasan","year":"2003","unstructured":"Srinivasan R, Su C, Lichtenstein GR: Medical therapy for Crohn\u2019s disease. In In The Clinician\u2019s Guide To Inflammatory Bowel Disease. Edited by Lichtenstein GR. Thorofare, NJ: Slack; 2003: 221\u2013254."},{"key":"41_CR6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, et al.: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease. Gastroenterology 2002, 122: 512\u2013530.","journal-title":"Gastroenterology"},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0889-8553(01)00010-3","volume":"31","author":"N Jani","year":"2002","unstructured":"Jani N, Regueiro MD: Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002, 31: 147\u2013166.","journal-title":"Gastroenterol Clin North Am"},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion","year":"2001","unstructured":"Faubion WA, Loftus EV, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121: 255\u2013260.","journal-title":"Gastroenterology"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00054725-199503000-00006","volume":"1","author":"WJ Sandborn","year":"1995","unstructured":"Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1: 48\u201363.","journal-title":"Inflamm Bowel Dis"},{"key":"41_CR10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","volume":"94","author":"RD Cohen","year":"1999","unstructured":"Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999, 94: 1587\u20131592.","journal-title":"Am J Gastroenterol"},{"key":"41_CR11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","volume":"120","author":"G D\u2019Haens","year":"2001","unstructured":"D\u2019Haens G, Lemmens L, Geboes K, et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120: 1323\u20131329.","journal-title":"Gastroenterology"},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","volume":"125","author":"G Assche van","year":"2003","unstructured":"van Assche G, D\u2019Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125: 1025\u20131031.","journal-title":"Gastroenterology"},{"key":"41_CR13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0889-8553(01)00011-5","volume":"31","author":"J Harrison","year":"2002","unstructured":"Harrison J, Hanauer SB: Medical treatment of Crohn\u2019s disease. Gastroenterol Clin North Am 2002, 31: 167\u2013184.","journal-title":"Gastroenterol Clin North Am"},{"key":"41_CR14","first-page":"423","volume":"91","author":"WJ Sandborn","year":"1996","unstructured":"Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91: 423\u2013433.","journal-title":"Am J Gastroenterol"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","volume":"118","author":"JD Lewis","year":"2000","unstructured":"Lewis JD, Schwartz JS, Lichtenstein GR: Azathioprine for maintenance of remission in Crohn\u2019s disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118: 1018\u20131024.","journal-title":"Gastroenterology"},{"key":"41_CR16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1046\/j.1365-2036.2001.01102.x","volume":"15","author":"OH Nielsen","year":"2001","unstructured":"Nielsen OH, Vainer B, Rask-Madsen J: Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001, 15: 1699\u20131708.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0016-5085(01)87938-5","volume":"120","author":"YX Yang","year":"2001","unstructured":"Yang YX, Lichtenstein GR: Methotrexate for the maintenance of remission in Crohn\u2019s disease. Gastroenterology 2001, 120: 1553\u20131558.","journal-title":"Gastroenterology"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"BG Feagan","year":"1995","unstructured":"Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn\u2019s disease. N Engl J Med 1995, 332: 292\u2013297.","journal-title":"N Engl J Med"},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","volume":"342","author":"BG Feagan","year":"2000","unstructured":"Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. N Engl J Med 2000, 342: 1627\u20131632.","journal-title":"N Engl J Med"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1572-0241.2000.02010.x","volume":"95","author":"T Orth","year":"2000","unstructured":"Orth T, Peters M, Schlaak JF, et al.: Mycophenolate moeftil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95: 1201\u20131207.","journal-title":"Am J Gastroenterol"},{"key":"41_CR21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gut.44.5.625","volume":"44","author":"MF Neurath","year":"1999","unstructured":"Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn\u2019s disease. Gut 1999, 44: 625\u2013628.","journal-title":"Gut"},{"key":"41_CR22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2036.2000.00695.x","volume":"14","author":"K Fellermann","year":"2000","unstructured":"Fellermann K, Steffen M, Stein J, et al.: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14: 171\u2013176.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR23","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1572-0241.1998.539_g.x","volume":"93","author":"K Fellermann","year":"1998","unstructured":"Fellermann K, Ludwig D, Stahl M, et al.: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998, 93: 1860\u20131866.","journal-title":"Am J Gastroenterol"},{"key":"41_CR24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Present DH, Isaacs K, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn\u2019s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125: 380\u2013388. A randomized, placebo-controlled trial showing clinical improvement but not remission of fistulous Crohn\u2019s disease with the use of oral tacrolimus.","journal-title":"Gastroenterology"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/S0002-9270(01)02494-7","volume":"96","author":"ME Blam","year":"2001","unstructured":"Blam ME, Stein RB, Lichtenstein GR: Integrating antitumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001, 96: 1977\u20131997.","journal-title":"Am J Gastroenterol"},{"key":"41_CR26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al.: A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn\u2019s disease. N Engl J Med 1997, 337: 1029\u20131035.","journal-title":"N Engl J Med"},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"PJ Rutgeerts","year":"1999","unstructured":"Rutgeerts PJ, D\u2019Haens G, Targan SR, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 1999, 117: 761\u2013769.","journal-title":"Gastroenterology"},{"key":"41_CR28","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2002.06026.x","volume":"97","author":"C Su","year":"2002","unstructured":"Su C, Salzberg BA, Lewis JD, et al.: Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002, 97: 2577\u20132584. Preliminary experience suggesting effectiveness of infliximab in the treatment of active ulcerative colitis.","journal-title":"Am J Gastroenterol"},{"key":"41_CR29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","volume":"349","author":"WA Stack","year":"1997","unstructured":"Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn\u2019s disease. Lancet 1997, 349: 521\u2013524.","journal-title":"Lancet"},{"key":"41_CR30","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","volume":"120","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn\u2019s disease: a randomized double-blind placebocontrolled trial. Gastroenterology 2001, 120: 1330\u20131338.","journal-title":"Gastroenterology"},{"key":"41_CR31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0889-8553(05)70059-5","volume":"28","author":"BE Sands","year":"1999","unstructured":"Sands BE: Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999, 28: 323\u2013351.","journal-title":"Gastroenterol Clin North Am"},{"key":"41_CR32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121: 1088\u20131094.","journal-title":"Gastroenterology"},{"key":"41_CR33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","volume":"17","author":"PJ Rutgeerts","year":"2003","unstructured":"Rutgeerts PJ, van Assche G, Noman M, et al.: Treatment of active Crohn\u2019s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17: 185\u2013192.","journal-title":"Aliment Pharmacol Ther"},{"key":"41_CR34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/gut.40.4.470","volume":"40","author":"J Bauditz","year":"1997","unstructured":"Bauditz J, Haemling J, Ortner M, et al.: Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn\u2019s disease. Gut 1997, 40: 470\u2013474.","journal-title":"Gut"},{"key":"41_CR35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","volume":"117","author":"EA Vasiliauskas","year":"1999","unstructured":"Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease. Gastroenterology 1999, 117: 1278\u20131287.","journal-title":"Gastroenterology"},{"key":"41_CR36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","volume":"117","author":"ED Ehrenpreis","year":"1999","unstructured":"Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy in patients with refractory Crohn\u2019s disease: an open-label trial. Gastroenterology 1999, 117: 1271\u20131277.","journal-title":"Gastroenterology"},{"key":"41_CR37","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","volume":"119","author":"S Schreiber","year":"2000","unstructured":"Schreiber S, Fedorak RN, Nielsen OH, et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease. Gastroenterology 2000, 119: 1461\u20131472.","journal-title":"Gastroenterology"},{"key":"41_CR38","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","volume":"119","author":"RN Fedorak","year":"2000","unstructured":"Fedorak RN, Gangl A, Elson CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn\u2019s disease. Gastroenterology 2000, 119: 1473\u20131482.","journal-title":"Gastroenterology"},{"key":"41_CR39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","volume":"117","author":"BE Sands","year":"1999","unstructured":"Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn\u2019s disease. Gastroenterology 1999, 117: 58\u201364.","journal-title":"Gastroenterology"},{"key":"41_CR40","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJM199403243301202","volume":"330","author":"RD Pullan","year":"1994","unstructured":"Pullan RD, Rhodes J, Ganesh S, et al.: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330: 811\u2013815.","journal-title":"N Engl J Med"},{"key":"41_CR41","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1572-0241.1999.01059.x","volume":"94","author":"WJ Sandborn","year":"1999","unstructured":"Sandborn WJ: Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999, 94: 1161\u20131171.","journal-title":"Am J Gastroenterol"},{"key":"41_CR42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/gast.2000.18159","volume":"119","author":"J Panes","year":"2000","unstructured":"Panes J, Esteve M, Cabre E, et al.: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000, 119: 903\u2013908.","journal-title":"Gastroenterology"},{"key":"41_CR43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"S Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn\u2019s disease. N Engl J Med 2003, 348: 24\u201332. An important randomized controlled trial demonstrating the effectiveness of natalizumab in active Crohn\u2019s disease. It showed improvement of remission rates at multiple time points.","journal-title":"N Engl J Med"},{"key":"41_CR44","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM200006013422203","volume":"342","author":"AE Slonim","year":"2000","unstructured":"Slonim AE, Bulone L, Damore MB, et al.: A preliminary study of growth hormone therapy for Crohn\u2019s disease. N Engl J Med 2000, 342: 1633\u20131677. A randomized, placebo-controlled trial suggesting benefit of human growth hormone in the treatment of chronically active Crohn\u2019s disease.","journal-title":"N Engl J Med"},{"key":"41_CR45","first-page":"3323","volume":"96","author":"JD Lewis","year":"2001","unstructured":"Lewis JD, Lichtenstein GR, Stein R, et al.: An open-label trial of the PPARg ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96: 3323\u20133328. A novel pilot study documenting the first reported use of PPAR\u00e3 ligand as therapy for ulcerative colitis in humans.","journal-title":"Am J Gastroenterol"},{"key":"41_CR46","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM199606133342401","volume":"334","author":"A Belluzzi","year":"1996","unstructured":"Belluzzi A, Brignola C, Campieri M, et al.: Effect of an enteric-coated fish oil preparation on relapses in Crohn\u2019s disease. N Engl J Med 1996, 334: 1557\u20131560.","journal-title":"N Engl J Med"},{"key":"41_CR47","unstructured":"Drug Topics Red Book, edn 107. Montvale, NJ: Thompson PDR; 2003."}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-004-0041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-004-0041-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-004-0041-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:57:00Z","timestamp":1559422620000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-004-0041-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11938-004-0041-1","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}